Soleno Therapeutics (NASDAQ:SLNO) Given Sell (D-) Rating at Weiss Ratings

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report)'s stock had its "sell (d-)" rating restated by equities research analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

SLNO has been the topic of a number of other reports. Guggenheim reissued a "buy" rating and set a $106.00 target price on shares of Soleno Therapeutics in a report on Wednesday, August 27th. HC Wainwright reissued a "buy" rating and set a $110.00 target price (up from $100.00) on shares of Soleno Therapeutics in a report on Monday, August 18th. Wall Street Zen raised Soleno Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, July 26th. Cowen reissued a "buy" rating on shares of Soleno Therapeutics in a report on Thursday, August 7th. Finally, Lifesci Capital raised Soleno Therapeutics to a "strong-buy" rating in a report on Wednesday, September 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Soleno Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $115.92.

Soleno Therapeutics Stock Up 1.0%

NASDAQ:SLNO opened at $62.74 on Wednesday. The firm has a market capitalization of $3.33 billion, a price-to-earnings ratio of -15.15 and a beta of -2.75. Soleno Therapeutics has a twelve month low of $41.50 and a twelve month high of $90.32. The stock's 50 day moving average price is $67.62 and its two-hundred day moving average price is $73.17. The company has a quick ratio of 15.01, a current ratio of 15.13 and a debt-to-equity ratio of 0.21.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.44. The company had revenue of $32.66 million for the quarter, compared to analyst estimates of $3.91 million. Equities research analysts expect that Soleno Therapeutics will post -3.72 earnings per share for the current fiscal year.

Institutional Trading of Soleno Therapeutics

Institutional investors have recently modified their holdings of the stock. Raymond James Financial Inc. bought a new stake in shares of Soleno Therapeutics during the 2nd quarter valued at $25,000. Nisa Investment Advisors LLC lifted its position in shares of Soleno Therapeutics by 287.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 539 shares of the company's stock valued at $45,000 after acquiring an additional 400 shares during the period. AlphaQuest LLC lifted its position in shares of Soleno Therapeutics by 37.5% during the 1st quarter. AlphaQuest LLC now owns 983 shares of the company's stock valued at $70,000 after acquiring an additional 268 shares during the period. Osaic Holdings Inc. lifted its position in shares of Soleno Therapeutics by 97.7% during the 2nd quarter. Osaic Holdings Inc. now owns 856 shares of the company's stock valued at $72,000 after acquiring an additional 423 shares during the period. Finally, KBC Group NV bought a new stake in shares of Soleno Therapeutics during the 2nd quarter valued at $77,000. 97.42% of the stock is currently owned by institutional investors.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.